$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

Biotech Sector Listings Defying Pandemic

 
• By Andrew McConaghie

The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.

Going public
The Nasdaq IPO gears the company up for a US commercial focus

More from Business

More from Scrip